Adamas' Series D Round Brings In $40 Million For Combination Antiviral Against Flu
This article was originally published in The Pink Sheet Daily
Executive Summary
Private firm begins unveiling itself gradually, including plans for a triple-combination antiviral drug therapy for severe flu.